Clinical Trial Update: Single-Dose Pharmacokinetics (PK) Study of Novel Neurogenic Compound NSI-189 [Phase 1]

View source ↗

Summary

A Phase 1 single-dose pharmacokinetic study of the neurogenic compound NSI-189 has been completed, supporting its development for depression.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• NSI-189 (NSI-189)

Snippet

Sponsor: Neuralstem Inc. | Conditions: Depression | Phase 1 | Status: COMPLETED